JP2013519733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519733A5 JP2013519733A5 JP2012554001A JP2012554001A JP2013519733A5 JP 2013519733 A5 JP2013519733 A5 JP 2013519733A5 JP 2012554001 A JP2012554001 A JP 2012554001A JP 2012554001 A JP2012554001 A JP 2012554001A JP 2013519733 A5 JP2013519733 A5 JP 2013519733A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- diazaspiro
- thioxo
- octane
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-Methyl-5- (5- (4- (5-methylfuran-2-yl) phenyl) -8-oxo-6-thioxo-5,7-diazaspiro [3.4] octane-7-yl) picoline Chemical compound 0.000 claims 90
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 19
- 150000001204 N-oxides Chemical class 0.000 claims 18
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 10
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- SOZCROHSZSTDMS-UHFFFAOYSA-N 3-methyl-5-[5-[4-(1-methylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1 SOZCROHSZSTDMS-UHFFFAOYSA-N 0.000 claims 2
- GWHMUKLWLWOKEZ-UHFFFAOYSA-N 3-methyl-5-[5-[4-(oxan-4-yl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C3CCOCC3)C2=S)=O)=C1 GWHMUKLWLWOKEZ-UHFFFAOYSA-N 0.000 claims 2
- LVWAAWKJSFHDLD-UHFFFAOYSA-N 3-methyl-5-[5-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1 LVWAAWKJSFHDLD-UHFFFAOYSA-N 0.000 claims 2
- GFTZDYAELZXEPO-UHFFFAOYSA-N 3-methyl-5-[5-[4-[methyl-(1-methylpiperidin-4-yl)amino]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound C=1C=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=CC=1N(C)C1CCN(C)CC1 GFTZDYAELZXEPO-UHFFFAOYSA-N 0.000 claims 2
- XYZCZKNVSIKKDE-UHFFFAOYSA-N 3-methyl-5-[8-oxo-5-(4-piperidin-4-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCNCC4)=CC=3)C2=S)=O)=C1 XYZCZKNVSIKKDE-UHFFFAOYSA-N 0.000 claims 2
- ZQFKCLBAKASGAF-UHFFFAOYSA-N 3-methyl-5-[8-oxo-5-(4-pyrimidin-4-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4N=CN=CC=4)=CC=3)C2=S)=O)=C1 ZQFKCLBAKASGAF-UHFFFAOYSA-N 0.000 claims 2
- XUAUKDIVVJMGON-UHFFFAOYSA-N 3-methyl-5-[8-oxo-5-(4-pyrimidin-5-ylphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C=3C=NC=NC=3)C2=S)=O)=C1 XUAUKDIVVJMGON-UHFFFAOYSA-N 0.000 claims 2
- DNESSPHSVVFMSP-UHFFFAOYSA-N 3-methyl-5-[8-oxo-6-sulfanylidene-5-[4-(thian-4-yloxy)phenyl]-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCSCC4)=CC=3)C2=S)=O)=C1 DNESSPHSVVFMSP-UHFFFAOYSA-N 0.000 claims 2
- JQDYZXQFIDMRQI-UHFFFAOYSA-N 3-methyl-5-[8-oxo-6-sulfanylidene-5-[4-[2-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethoxy]phenyl]-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OCCN4CCN(CC(F)(F)F)CC4)=CC=3)C2=S)=O)=C1 JQDYZXQFIDMRQI-UHFFFAOYSA-N 0.000 claims 2
- GWUQRAATVBDXDF-UHFFFAOYSA-N 5-[4,4-dimethyl-3-[4-(1-methylpiperidin-4-yl)oxyphenyl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C(C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)(C)C)C=C1 GWUQRAATVBDXDF-UHFFFAOYSA-N 0.000 claims 2
- PFNGNGXNXGPNOE-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(1-methylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1F PFNGNGXNXGPNOE-UHFFFAOYSA-N 0.000 claims 2
- VUHIUQUILSBVEV-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyridin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(N(C3(CCC3)C2=O)C=2C=C(F)C(OCCC=3N=CC=CC=3)=CC=2)=S)=C1 VUHIUQUILSBVEV-UHFFFAOYSA-N 0.000 claims 2
- JJXJUZNVQHZJFJ-UHFFFAOYSA-N 5-[5-[4-(1-acetylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(C(=O)C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1 JJXJUZNVQHZJFJ-UHFFFAOYSA-N 0.000 claims 2
- FQLZLXIGQATCIG-UHFFFAOYSA-N 5-[5-[4-(1-ethylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(CC)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1 FQLZLXIGQATCIG-UHFFFAOYSA-N 0.000 claims 2
- IZKSMIBPGSWAMO-UHFFFAOYSA-N 5-[5-[4-(1-methylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 IZKSMIBPGSWAMO-UHFFFAOYSA-N 0.000 claims 2
- VRRBGSJTHVLHDZ-UHFFFAOYSA-N 5-[5-[4-(2-hydroxyethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(N(C3(CCC3)C2=O)C=2C=CC(OCCO)=CC=2)=S)=C1 VRRBGSJTHVLHDZ-UHFFFAOYSA-N 0.000 claims 2
- ZRFJEPHTKCMGHU-UHFFFAOYSA-N 5-[5-[4-(furan-2-yl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C=3OC=CC=3)C2=S)=O)=C1 ZRFJEPHTKCMGHU-UHFFFAOYSA-N 0.000 claims 2
- IHSQMNGMZJCMPE-UHFFFAOYSA-N 5-[5-[4-[1-(2-hydroxyethyl)piperidin-4-yl]oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCN(CCO)CC4)=CC=3)C2=S)=O)=C1 IHSQMNGMZJCMPE-UHFFFAOYSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FIUWVDPKEKMPCB-UHFFFAOYSA-N n-benzyl-4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(F)C(C(=O)NCC=4C=CC=CC=4)=CC=3)C2=S)=O)=C1 FIUWVDPKEKMPCB-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- JLBHKUINOKERHR-UHFFFAOYSA-N 2-[4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorophenoxy]acetic acid Chemical compound C1=C(F)C(OCC(=O)O)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S JLBHKUINOKERHR-UHFFFAOYSA-N 0.000 claims 1
- LXWGAUWSAAIJEJ-UHFFFAOYSA-N 2-chloro-4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-n-methylbenzamide Chemical compound C1=C(Cl)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S LXWGAUWSAAIJEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- PFVXQYLOGPVQIQ-UHFFFAOYSA-N 3-methyl-5-[5-(4-methylphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S PFVXQYLOGPVQIQ-UHFFFAOYSA-N 0.000 claims 1
- WHYHOPOYOMDCND-UHFFFAOYSA-N 3-methyl-5-[5-[4-(oxan-4-yloxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCOCC4)=CC=3)C2=S)=O)=C1 WHYHOPOYOMDCND-UHFFFAOYSA-N 0.000 claims 1
- VEEWFTBJCDKMFG-UHFFFAOYSA-N 3-methyl-5-[8-oxo-5-(1-oxo-2,3-dihydroisoindol-5-yl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C4CNC(=O)C4=CC=3)C2=S)=O)=C1 VEEWFTBJCDKMFG-UHFFFAOYSA-N 0.000 claims 1
- KQCYLVRSFOSILF-UHFFFAOYSA-N 4-[3-(6-cyano-5-methylpyridin-3-yl)-4-oxo-2-sulfanylidene-1,3-diazaspiro[4.4]nonan-1-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S KQCYLVRSFOSILF-UHFFFAOYSA-N 0.000 claims 1
- PSEOJESETBLUFD-UHFFFAOYSA-N 4-[3-(6-cyano-5-methylpyridin-3-yl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S PSEOJESETBLUFD-UHFFFAOYSA-N 0.000 claims 1
- UYXYRTFATQAQAS-UHFFFAOYSA-N 4-[4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-n-methylbutanamide Chemical compound C1=CC(CCCC(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S UYXYRTFATQAQAS-UHFFFAOYSA-N 0.000 claims 1
- XWJMMBMYSZWGCF-UHFFFAOYSA-N 4-[4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-n-phenylbutanamide Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(CCCC(=O)NC=4C=CC=CC=4)=CC=3)C2=S)=O)=C1 XWJMMBMYSZWGCF-UHFFFAOYSA-N 0.000 claims 1
- KBWRKNQMMLRXOI-UHFFFAOYSA-N 4-[4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butanoic acid Chemical compound C1=CC(CCCC(=O)O)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S KBWRKNQMMLRXOI-UHFFFAOYSA-N 0.000 claims 1
- BJEKZZGIVOGAOQ-UHFFFAOYSA-N 4-[5-[3-fluoro-4-(pyridin-2-ylmethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC=1C=C(C=CC1OCC1=NC=CC=C1)N1C2(CCC2)C(N(C1=S)C1=C(C(=NC=C1)C#N)C(F)(F)F)=O BJEKZZGIVOGAOQ-UHFFFAOYSA-N 0.000 claims 1
- GDCHOKLGRGKVMO-UHFFFAOYSA-N 4-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound FC=1C=C(C=CC1OCCN1CCN(CC1)C)N1C2(CCC2)C(N(C1=S)C1=C(C(=NC=C1)C#N)C)=O GDCHOKLGRGKVMO-UHFFFAOYSA-N 0.000 claims 1
- VQSJNXIZPZRIMD-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S VQSJNXIZPZRIMD-UHFFFAOYSA-N 0.000 claims 1
- OWBOYJJBJQIVCA-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-n-phenylbenzamide Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(F)C(C(=O)NC=4C=CC=CC=4)=CC=3)C2=S)=O)=C1 OWBOYJJBJQIVCA-UHFFFAOYSA-N 0.000 claims 1
- CZWQHDBTXQFGRT-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(F)C(C(N)=O)=CC=3)C2=S)=O)=C1 CZWQHDBTXQFGRT-UHFFFAOYSA-N 0.000 claims 1
- BQFIXNZVJIVJQN-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzoic acid Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(F)C(C(O)=O)=CC=3)C2=S)=O)=C1 BQFIXNZVJIVJQN-UHFFFAOYSA-N 0.000 claims 1
- QXTCKMVDEQMWCT-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-methoxy-n-methylbenzamide Chemical compound C1=C(OC)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S QXTCKMVDEQMWCT-UHFFFAOYSA-N 0.000 claims 1
- PFORSEQBJTVFKL-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-methylbenzamide Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(C)C(C(N)=O)=CC=3)C2=S)=O)=C1 PFORSEQBJTVFKL-UHFFFAOYSA-N 0.000 claims 1
- FFPWNPQZIBQVON-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-3-fluoro-n-methylbenzamide Chemical compound FC1=CC(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S FFPWNPQZIBQVON-UHFFFAOYSA-N 0.000 claims 1
- CQVYNPGOIJMDNU-UHFFFAOYSA-N 4-[7-(6-cyano-5-methylpyridin-3-yl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S CQVYNPGOIJMDNU-UHFFFAOYSA-N 0.000 claims 1
- DSOHEDKSYJTFLO-UHFFFAOYSA-N 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-n-(2-methoxyethyl)-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)N(C)CCOC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S DSOHEDKSYJTFLO-UHFFFAOYSA-N 0.000 claims 1
- IZDSIQAAIRTBOF-UHFFFAOYSA-N 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-n-(2-phenylethyl)benzamide Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1C(=O)NCCC1=CC=CC=C1 IZDSIQAAIRTBOF-UHFFFAOYSA-N 0.000 claims 1
- UXCAOZJACNSXAP-UHFFFAOYSA-N 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-n-(cyclopentylmethyl)-2-fluorobenzamide Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1C(=O)NCC1CCCC1 UXCAOZJACNSXAP-UHFFFAOYSA-N 0.000 claims 1
- AKCSLMGBODOOIQ-UHFFFAOYSA-N 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-n-[3-(3,3-difluoropyrrolidin-1-yl)propyl]-2-fluorobenzamide Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1C(=O)NCCCN1CCC(F)(F)C1 AKCSLMGBODOOIQ-UHFFFAOYSA-N 0.000 claims 1
- BKHKLNBPVJGWFO-UHFFFAOYSA-N 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-n-[3-[cyclopentyl(methyl)amino]propyl]-2-fluorobenzamide Chemical compound C1CCCC1N(C)CCCNC(=O)C(C(=C1)F)=CC=C1N1C(=S)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C(=O)C11CCC1 BKHKLNBPVJGWFO-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- VPQRCWLVUKXIHZ-UHFFFAOYSA-N 5-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C(C)(C)N(C=3C=CC(O)=CC=3)C2=S)=O)=C1 VPQRCWLVUKXIHZ-UHFFFAOYSA-N 0.000 claims 1
- NWJZMCBPAIXDRV-UHFFFAOYSA-N 5-[4,4-dimethyl-3-[4-(1-methylpiperidin-4-yl)oxyphenyl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C(C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)(C)C)C=C1 NWJZMCBPAIXDRV-UHFFFAOYSA-N 0.000 claims 1
- YCZMFHUGRIRFMD-UHFFFAOYSA-N 5-[4-(2-pyridin-2-ylethoxy)phenyl]-6-sulfanylidene-7-[3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-5,7-diazaspiro[3.4]octan-8-one Chemical compound N=1N2C(C(F)(F)F)=NN=C2C=CC=1N(C(C12CCC2)=O)C(=S)N1C(C=C1)=CC=C1OCCC1=CC=CC=N1 YCZMFHUGRIRFMD-UHFFFAOYSA-N 0.000 claims 1
- MBBZZDQDDGIDAP-UHFFFAOYSA-N 5-[5-(3-fluoro-4-hydroxyphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=C(F)C(O)=CC=3)C2=S)=O)=C1 MBBZZDQDDGIDAP-UHFFFAOYSA-N 0.000 claims 1
- OEPPPIDELDAHPH-UHFFFAOYSA-N 5-[5-(3-fluoro-4-phenylmethoxyphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCC1=CC=CC=C1 OEPPPIDELDAHPH-UHFFFAOYSA-N 0.000 claims 1
- XEEPHBJBYRDKOE-UHFFFAOYSA-N 5-[5-(4-fluoro-3-phenylmethoxyphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCC1=CC=CC=C1 XEEPHBJBYRDKOE-UHFFFAOYSA-N 0.000 claims 1
- WVXUVKDUFMVDKZ-UHFFFAOYSA-N 5-[5-(4-hydroxyphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(O)=CC=3)C2=S)=O)=C1 WVXUVKDUFMVDKZ-UHFFFAOYSA-N 0.000 claims 1
- ACHMJTJKFYOMTK-UHFFFAOYSA-N 5-[5-(4-methoxyphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C)C(C#N)=NC=2)C1=S ACHMJTJKFYOMTK-UHFFFAOYSA-N 0.000 claims 1
- QLUKKOHDOHPNCS-UHFFFAOYSA-N 5-[5-[2-(hydroxymethyl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound OCC1=CC=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S QLUKKOHDOHPNCS-UHFFFAOYSA-N 0.000 claims 1
- DWTKNMDBHTUATB-UHFFFAOYSA-N 5-[5-[2-fluoro-4-(1-methylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC(C=C1F)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S DWTKNMDBHTUATB-UHFFFAOYSA-N 0.000 claims 1
- NWAMOJYJAXAIPE-UHFFFAOYSA-N 5-[5-[2-fluoro-4-(2-methoxyethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(OCCOC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S NWAMOJYJAXAIPE-UHFFFAOYSA-N 0.000 claims 1
- QRFGOQKUZFZHTD-UHFFFAOYSA-N 5-[5-[2-fluoro-4-(2-piperidin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C=1C=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C(F)=CC=1OCCN1CCCCC1 QRFGOQKUZFZHTD-UHFFFAOYSA-N 0.000 claims 1
- ONZSHTYAKXRLSG-UHFFFAOYSA-N 5-[5-[2-fluoro-4-(2-pyridin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C=1C=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C(F)=CC=1OCCC1=CC=CC=N1 ONZSHTYAKXRLSG-UHFFFAOYSA-N 0.000 claims 1
- FMYJSGCAKSIFEE-UHFFFAOYSA-N 5-[5-[2-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC(C=C1F)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S FMYJSGCAKSIFEE-UHFFFAOYSA-N 0.000 claims 1
- PBPWDARAEUASIQ-UHFFFAOYSA-N 5-[5-[2-fluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC(C=C1F)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S PBPWDARAEUASIQ-UHFFFAOYSA-N 0.000 claims 1
- QXBDTTBOFBXJFB-UHFFFAOYSA-N 5-[5-[3-(hydroxymethyl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound OCC1=CC=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 QXBDTTBOFBXJFB-UHFFFAOYSA-N 0.000 claims 1
- WBQCPZQAUXTEBH-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(1-methylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F WBQCPZQAUXTEBH-UHFFFAOYSA-N 0.000 claims 1
- PAOVBAVZIJKHQG-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-methoxyethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(F)C(OCCOC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S PAOVBAVZIJKHQG-UHFFFAOYSA-N 0.000 claims 1
- NLJSEGPDOLJKAB-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-methoxyethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]quinoline-8-carbonitrile Chemical compound C1=C(F)C(OCCOC)=CC=C1N1C2(CCC2)C(=O)N(C=2C3=CC=CN=C3C(C#N)=CC=2)C1=S NLJSEGPDOLJKAB-UHFFFAOYSA-N 0.000 claims 1
- HVVRFIVGBXLFMK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-morpholin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCOCC1 HVVRFIVGBXLFMK-UHFFFAOYSA-N 0.000 claims 1
- OHVGXDSTBODDEW-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-naphthalen-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OCCC=2C3=CC=CC=C3C=CC=2)C(F)=CC=1N1C(=S)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C(=O)C11CCC1 OHVGXDSTBODDEW-UHFFFAOYSA-N 0.000 claims 1
- GXYDZCAOIHQVFZ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-naphthalen-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OCCC=2C=C3C=CC=CC3=CC=2)C(F)=CC=1N1C(=S)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C(=O)C11CCC1 GXYDZCAOIHQVFZ-UHFFFAOYSA-N 0.000 claims 1
- ZRVHHWOBMQBXSK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-piperazin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCNCC1 ZRVHHWOBMQBXSK-UHFFFAOYSA-N 0.000 claims 1
- ZMJBPTVKTDLBLX-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-piperidin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCCCC1 ZMJBPTVKTDLBLX-UHFFFAOYSA-N 0.000 claims 1
- LYQLACIBDYBBNJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyrazin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1=CN=CC=N1 LYQLACIBDYBBNJ-UHFFFAOYSA-N 0.000 claims 1
- SYIGKDOJZXKSGW-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyridin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1=CC=CC=N1 SYIGKDOJZXKSGW-UHFFFAOYSA-N 0.000 claims 1
- MGYPKBHPISMKPB-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyridin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]quinoline-8-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C3=CC=CN=C3C(C#N)=CC=2)=CC=C1OCCC1=CC=CC=N1 MGYPKBHPISMKPB-UHFFFAOYSA-N 0.000 claims 1
- JTYPBNVFWRBDHA-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyridin-3-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1=CC=CN=C1 JTYPBNVFWRBDHA-UHFFFAOYSA-N 0.000 claims 1
- OTTGMBYHMUKZCE-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyridin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1=CC=NC=C1 OTTGMBYHMUKZCE-UHFFFAOYSA-N 0.000 claims 1
- DFWQDLLHPFXXLX-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyrimidin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1=NC=CC=N1 DFWQDLLHPFXXLX-UHFFFAOYSA-N 0.000 claims 1
- QKZUVBSZEVAFPA-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyrrol-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1C=CC=C1 QKZUVBSZEVAFPA-UHFFFAOYSA-N 0.000 claims 1
- LFTPCKCORZZBKJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCCC1 LFTPCKCORZZBKJ-UHFFFAOYSA-N 0.000 claims 1
- QSWTVCLLOKZVCI-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-thiomorpholin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCSCC1 QSWTVCLLOKZVCI-UHFFFAOYSA-N 0.000 claims 1
- GLVBTDCHSFZUKJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3,3,4,4,4-pentafluorobutoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 GLVBTDCHSFZUKJ-UHFFFAOYSA-N 0.000 claims 1
- FOCHZLGBEJVMIG-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCN1CCOCC1 FOCHZLGBEJVMIG-UHFFFAOYSA-N 0.000 claims 1
- UBTDHKAIJJZOJI-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-phenylmethoxypropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCOCC1=CC=CC=C1 UBTDHKAIJJZOJI-UHFFFAOYSA-N 0.000 claims 1
- CGEHPFKGNCVJJC-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-phenylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCC1=CC=CC=C1 CGEHPFKGNCVJJC-UHFFFAOYSA-N 0.000 claims 1
- AHRMLHQZCMFSRJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-pyridin-3-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCC1=CC=CN=C1 AHRMLHQZCMFSRJ-UHFFFAOYSA-N 0.000 claims 1
- RBSHCUVYELMIBG-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-pyrrolidin-1-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCN1CCCC1 RBSHCUVYELMIBG-UHFFFAOYSA-N 0.000 claims 1
- DCNPTWVMZYRLEM-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(4,4,5,5,5-pentafluoropentoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 DCNPTWVMZYRLEM-UHFFFAOYSA-N 0.000 claims 1
- UZLUQSICCSUPHJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(4-methoxybutoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(F)C(OCCCCOC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S UZLUQSICCSUPHJ-UHFFFAOYSA-N 0.000 claims 1
- WESSOLUFLTTZBU-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(4-phenylmethoxybutoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCCOCC1=CC=CC=C1 WESSOLUFLTTZBU-UHFFFAOYSA-N 0.000 claims 1
- XJFZAXKSVOZIHZ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(pyridin-3-ylmethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCC1=CC=CN=C1 XJFZAXKSVOZIHZ-UHFFFAOYSA-N 0.000 claims 1
- HMRAEVWWMRHUND-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(pyridin-4-ylmethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCC1=CC=NC=C1 HMRAEVWWMRHUND-UHFFFAOYSA-N 0.000 claims 1
- VKBPOCNCENEHFD-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(2-methylphenyl)ethyl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC=1C=C(C=CC=1CCC1=C(C=CC=C1)C)N1C2(CCC2)C(N(C1=S)C=1C=C(C(=NC=1)C#N)C(F)(F)F)=O VKBPOCNCENEHFD-UHFFFAOYSA-N 0.000 claims 1
- QVIPNGFOGROOMX-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(2-methylpyrazol-3-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound CN1N=CC=C1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F QVIPNGFOGROOMX-UHFFFAOYSA-N 0.000 claims 1
- KRFVGLPKICDNDQ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F KRFVGLPKICDNDQ-UHFFFAOYSA-N 0.000 claims 1
- ZZVWEKVZWXQPTE-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1F ZZVWEKVZWXQPTE-UHFFFAOYSA-N 0.000 claims 1
- XATXAKDKRVQPKQ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]quinoline-8-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C3=CC=CN=C3C(C#N)=CC=2)C=C1F XATXAKDKRVQPKQ-UHFFFAOYSA-N 0.000 claims 1
- BADLCTYXYFEZGY-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(oxan-4-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1CCOCC1 BADLCTYXYFEZGY-UHFFFAOYSA-N 0.000 claims 1
- RMUMFNZIBMTECT-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[3-(4,4,5,5,5-pentafluoropentylsulfanyl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCCSCCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 RMUMFNZIBMTECT-UHFFFAOYSA-N 0.000 claims 1
- ZLUCPQCVVPJGSN-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[3-(4,4,5,5,5-pentafluoropentylsulfinyl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCCS(=O)CCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 ZLUCPQCVVPJGSN-UHFFFAOYSA-N 0.000 claims 1
- NWZHJVULIKUIBK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F NWZHJVULIKUIBK-UHFFFAOYSA-N 0.000 claims 1
- ICQITHVRCGACKI-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[4-(4,4,5,5,5-pentafluoropentylsulfanyl)butoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCCCSCCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 ICQITHVRCGACKI-UHFFFAOYSA-N 0.000 claims 1
- IESUTKQUJDDTSO-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[4-(4,4,5,5,5-pentafluoropentylsulfinyl)butoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=C(OCCCCS(=O)CCCC(F)(F)C(F)(F)F)C(F)=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=C1 IESUTKQUJDDTSO-UHFFFAOYSA-N 0.000 claims 1
- QMFGDZXBAUCNRG-UHFFFAOYSA-N 5-[5-[4-(1-methylsulfonylpiperidin-4-yl)oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(S(=O)(=O)C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 QMFGDZXBAUCNRG-UHFFFAOYSA-N 0.000 claims 1
- XKLMTWURFLUKNC-UHFFFAOYSA-N 5-[5-[4-(2-cyclohexylethoxy)-3-fluorophenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCC1CCCCC1 XKLMTWURFLUKNC-UHFFFAOYSA-N 0.000 claims 1
- GAPISYYCDKRIRO-UHFFFAOYSA-N 5-[5-[4-(4-methylpiperazin-1-yl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1C1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 GAPISYYCDKRIRO-UHFFFAOYSA-N 0.000 claims 1
- LEOWQLRNMSECIU-UHFFFAOYSA-N 5-[5-[4-(hydroxymethyl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1=CC(CO)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S LEOWQLRNMSECIU-UHFFFAOYSA-N 0.000 claims 1
- JKAINRVJAFQEIB-UHFFFAOYSA-N 5-[5-[4-(oxan-4-yl)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C3CCOCC3)C2=S)=O)=C1 JKAINRVJAFQEIB-UHFFFAOYSA-N 0.000 claims 1
- FIWSMWULRZEMSV-UHFFFAOYSA-N 5-[5-[4-(oxan-4-yloxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCOCC4)=CC=3)C2=S)=O)=C1 FIWSMWULRZEMSV-UHFFFAOYSA-N 0.000 claims 1
- ZOHYFZCHLBMNSR-UHFFFAOYSA-N 5-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 ZOHYFZCHLBMNSR-UHFFFAOYSA-N 0.000 claims 1
- WTAHFJDHSTTWKS-UHFFFAOYSA-N 5-[5-[4-[1-(2-hydroxyethyl)piperidin-4-yl]oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(CCO)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 WTAHFJDHSTTWKS-UHFFFAOYSA-N 0.000 claims 1
- VIRBWSAYMWBJQJ-UHFFFAOYSA-N 5-[5-[4-[1-(2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C(=O)C(C)C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 VIRBWSAYMWBJQJ-UHFFFAOYSA-N 0.000 claims 1
- OIVJRRMSWYNYQX-UHFFFAOYSA-N 5-[5-[4-[2-(4-acetylpiperazin-1-yl)ethoxy]-3-fluorophenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F OIVJRRMSWYNYQX-UHFFFAOYSA-N 0.000 claims 1
- GDINBDLWXJOGEW-UHFFFAOYSA-N 5-[5-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 GDINBDLWXJOGEW-UHFFFAOYSA-N 0.000 claims 1
- GQFXTTRTKDXGCZ-UHFFFAOYSA-N 5-[5-[4-[3-(4-methylpiperazin-1-yl)propyl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 GQFXTTRTKDXGCZ-UHFFFAOYSA-N 0.000 claims 1
- CGKDLVLWRSDAGZ-UHFFFAOYSA-N 5-[5-[4-[[methyl(pyridin-4-ylmethyl)amino]methyl]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C=1C=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=CC=1CN(C)CC1=CC=NC=C1 CGKDLVLWRSDAGZ-UHFFFAOYSA-N 0.000 claims 1
- DANLBLHNDJGDKM-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(2-morpholin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCN1CCOCC1 DANLBLHNDJGDKM-UHFFFAOYSA-N 0.000 claims 1
- CFGSNPAKSWHURT-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(2-pyridin-2-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCC1=CC=CC=N1 CFGSNPAKSWHURT-UHFFFAOYSA-N 0.000 claims 1
- LNLJFGGBDDPZJM-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(2-pyridin-3-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCC1=CC=CN=C1 LNLJFGGBDDPZJM-UHFFFAOYSA-N 0.000 claims 1
- KHMBHQBJFMCZAR-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(2-pyridin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCC1=CC=NC=C1 KHMBHQBJFMCZAR-UHFFFAOYSA-N 0.000 claims 1
- VZNBTTGXYYWIPI-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(3-morpholin-4-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCCN1CCOCC1 VZNBTTGXYYWIPI-UHFFFAOYSA-N 0.000 claims 1
- YCXPNRJXPUBSDO-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(3-phenylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCCC1=CC=CC=C1 YCXPNRJXPUBSDO-UHFFFAOYSA-N 0.000 claims 1
- NIVRTVOACSMZEF-UHFFFAOYSA-N 5-[5-[4-fluoro-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1F NIVRTVOACSMZEF-UHFFFAOYSA-N 0.000 claims 1
- QYTWADPOXANMJX-UHFFFAOYSA-N 5-[5-[4-fluoro-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1F QYTWADPOXANMJX-UHFFFAOYSA-N 0.000 claims 1
- BTNDDYSVEMYGKR-UHFFFAOYSA-N 5-[8-oxo-5-(4-piperazin-1-ylphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)N3CCNCC3)C2=S)=O)=C1 BTNDDYSVEMYGKR-UHFFFAOYSA-N 0.000 claims 1
- BJYQIDOKTISRPH-UHFFFAOYSA-N 5-[8-oxo-5-(4-piperidin-4-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCNCC4)=CC=3)C2=S)=O)=C1 BJYQIDOKTISRPH-UHFFFAOYSA-N 0.000 claims 1
- AIKJXYNJPLTGIA-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyrazin-2-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4N=CC=NC=4)=CC=3)C2=S)=O)=C1 AIKJXYNJPLTGIA-UHFFFAOYSA-N 0.000 claims 1
- KILXQKVVRRFUBG-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-2-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4N=CC=CC=4)=CC=3)C2=S)=O)=C1 KILXQKVVRRFUBG-UHFFFAOYSA-N 0.000 claims 1
- FEINGVBQGSPBEL-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-2-ylphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C=3N=CC=CC=3)C2=S)=O)=C1 FEINGVBQGSPBEL-UHFFFAOYSA-N 0.000 claims 1
- RRMOJHSIXCZJQU-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-3-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4C=NC=CC=4)=CC=3)C2=S)=O)=C1 RRMOJHSIXCZJQU-UHFFFAOYSA-N 0.000 claims 1
- GCUJCHMGHABHBU-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-3-ylphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C=3C=NC=CC=3)C2=S)=O)=C1 GCUJCHMGHABHBU-UHFFFAOYSA-N 0.000 claims 1
- PKCMXGNBKZCERU-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-4-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4C=CN=CC=4)=CC=3)C2=S)=O)=C1 PKCMXGNBKZCERU-UHFFFAOYSA-N 0.000 claims 1
- ACSYUVQFZDPHGM-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyridin-4-ylphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)C=3C=CN=CC=3)C2=S)=O)=C1 ACSYUVQFZDPHGM-UHFFFAOYSA-N 0.000 claims 1
- KWSKIGKYFHJMPD-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyrimidin-2-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4N=CC=CN=4)=CC=3)C2=S)=O)=C1 KWSKIGKYFHJMPD-UHFFFAOYSA-N 0.000 claims 1
- YUQMRQSRHSDNRV-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyrimidin-4-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4N=CN=CC=4)=CC=3)C2=S)=O)=C1 YUQMRQSRHSDNRV-UHFFFAOYSA-N 0.000 claims 1
- DHGPARSOBHQAHW-UHFFFAOYSA-N 5-[8-oxo-5-(4-pyrimidin-5-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(OC=4C=NC=NC=4)=CC=3)C2=S)=O)=C1 DHGPARSOBHQAHW-UHFFFAOYSA-N 0.000 claims 1
- IAGNTBCWOBVBTQ-UHFFFAOYSA-N 5-[8-oxo-5-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 IAGNTBCWOBVBTQ-UHFFFAOYSA-N 0.000 claims 1
- IOLAOEJRBKSAAN-UHFFFAOYSA-N 5-[8-oxo-5-[4-(1-propanoylpiperidin-4-yl)oxyphenyl]-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C(=O)CC)CCC1OC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 IOLAOEJRBKSAAN-UHFFFAOYSA-N 0.000 claims 1
- IMTPSUIYCSLJCS-UHFFFAOYSA-N 5-[8-oxo-5-[4-(2-pyridin-4-ylethylsulfonyl)phenyl]-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C(F)(F)F)=CC(N2C(C3(CCC3)N(C=3C=CC(=CC=3)S(=O)(=O)CCC=3C=CN=CC=3)C2=S)=O)=C1 IMTPSUIYCSLJCS-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- SKYFUZLTKFEKBU-UHFFFAOYSA-N C(#N)C1=C(C=C(C=N1)N1C(NC2(CCC2)C1=O)=S)C(F)(F)F Chemical compound C(#N)C1=C(C=C(C=N1)N1C(NC2(CCC2)C1=O)=S)C(F)(F)F SKYFUZLTKFEKBU-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010036940 Prostatic adenoma Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 210000000579 abdominal fat Anatomy 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- AOQMMUWCTVLKPT-UHFFFAOYSA-N n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCCN1CCCC1 AOQMMUWCTVLKPT-UHFFFAOYSA-N 0.000 claims 1
- XQEKIKDRHDFDBG-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1C(=O)NCC1=CC=CC=C1Cl XQEKIKDRHDFDBG-UHFFFAOYSA-N 0.000 claims 1
- YGJKICLNQWOKEC-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1C(=O)NCC1=CC=CC(Cl)=C1 YGJKICLNQWOKEC-UHFFFAOYSA-N 0.000 claims 1
- BHTTVIYBOTUFIT-UHFFFAOYSA-N n-[2-(4-bromo-2-methylpyrazol-3-yl)ethyl]-4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide Chemical compound CN1N=CC(Br)=C1CCNC(=O)C1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F BHTTVIYBOTUFIT-UHFFFAOYSA-N 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000021595 spermatogenesis Effects 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30508210P | 2010-02-16 | 2010-02-16 | |
| US61/305,082 | 2010-02-16 | ||
| US32902310P | 2010-04-28 | 2010-04-28 | |
| US61/329,023 | 2010-04-28 | ||
| US38845710P | 2010-09-30 | 2010-09-30 | |
| US61/388,457 | 2010-09-30 | ||
| PCT/US2011/025106 WO2011103202A2 (en) | 2010-02-16 | 2011-02-16 | Androgen receptor modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016073172A Division JP6141484B2 (ja) | 2010-02-16 | 2016-03-31 | アンドロゲン受容体モジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519733A JP2013519733A (ja) | 2013-05-30 |
| JP2013519733A5 true JP2013519733A5 (OSRAM) | 2014-04-03 |
| JP5918147B2 JP5918147B2 (ja) | 2016-05-18 |
Family
ID=44483553
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554001A Expired - Fee Related JP5918147B2 (ja) | 2010-02-16 | 2011-02-16 | アンドロゲン受容体モジュレーターおよびその使用 |
| JP2016073172A Expired - Fee Related JP6141484B2 (ja) | 2010-02-16 | 2016-03-31 | アンドロゲン受容体モジュレーターおよびその使用 |
| JP2017091441A Expired - Fee Related JP6391076B2 (ja) | 2010-02-16 | 2017-05-01 | アンドロゲン受容体モジュレーターおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016073172A Expired - Fee Related JP6141484B2 (ja) | 2010-02-16 | 2016-03-31 | アンドロゲン受容体モジュレーターおよびその使用 |
| JP2017091441A Expired - Fee Related JP6391076B2 (ja) | 2010-02-16 | 2017-05-01 | アンドロゲン受容体モジュレーターおよびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9108944B2 (OSRAM) |
| EP (4) | EP2536708A4 (OSRAM) |
| JP (3) | JP5918147B2 (OSRAM) |
| KR (2) | KR101819199B1 (OSRAM) |
| CN (3) | CN103724322B (OSRAM) |
| AU (1) | AU2011218173C1 (OSRAM) |
| BR (1) | BR112012020558B1 (OSRAM) |
| CA (1) | CA2787083C (OSRAM) |
| CY (1) | CY1120297T1 (OSRAM) |
| DK (1) | DK3124481T3 (OSRAM) |
| EA (3) | EA028869B1 (OSRAM) |
| ES (1) | ES2668380T3 (OSRAM) |
| HR (1) | HRP20180848T1 (OSRAM) |
| HU (1) | HUE037389T2 (OSRAM) |
| IL (3) | IL220703A (OSRAM) |
| LT (1) | LT3124481T (OSRAM) |
| MX (2) | MX355915B (OSRAM) |
| PH (3) | PH12012501652A1 (OSRAM) |
| PL (1) | PL3124481T3 (OSRAM) |
| PT (1) | PT3124481T (OSRAM) |
| RS (1) | RS57309B1 (OSRAM) |
| SG (3) | SG10201907588XA (OSRAM) |
| SI (1) | SI3124481T1 (OSRAM) |
| SM (1) | SMT201800277T1 (OSRAM) |
| WO (1) | WO2011103202A2 (OSRAM) |
| ZA (2) | ZA201507863B (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028869B1 (ru) | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Модуляторы рецептора андрогенов и их применение |
| RU2598854C2 (ru) * | 2011-03-10 | 2016-09-27 | Сучжоу Кинтор Фармасьютикалз, Инк. | Производные тиогидантоина, полезные в качестве антагонистов рецептора андрогена |
| WO2013056547A1 (zh) * | 2011-10-22 | 2013-04-25 | Chen Degui | 一组乙内酰脲衍生物的合成及其应用 |
| PE20150099A1 (es) | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos |
| US9650382B2 (en) | 2012-01-13 | 2017-05-16 | Aranda Pharma Ltd | Heteroarylamide derivatives having antiandrogenic properties |
| UY34646A (es) | 2012-03-02 | 2013-10-31 | Novartis Ag | Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos |
| JP6182209B2 (ja) | 2012-06-07 | 2017-08-16 | アラゴン ファーマシューティカルズ，インコーポレイテッド | アンドロゲン受容体変調剤の結晶質形態 |
| MY180834A (en) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| AR092982A1 (es) | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | Modulacion de la expresion de receptores androgenicos |
| WO2014075387A1 (zh) * | 2012-11-14 | 2014-05-22 | 上海医药集团股份有限公司 | 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| AU2014273618B2 (en) * | 2013-05-29 | 2016-10-13 | Hinova Pharmaceuticals Inc. | Imidazole diketone compound and use thereof |
| WO2015018356A1 (zh) * | 2013-08-08 | 2015-02-12 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| CN103601671B (zh) * | 2013-10-22 | 2016-08-17 | 上海泰坦科技股份有限公司 | 碘代三氟甲基吡啶的制备方法 |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN103694243B (zh) * | 2013-12-20 | 2015-09-09 | 中国农业大学 | 2-取代吡啶基-1,2,4-三唑并[1,2-a]哒嗪化合物 |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| MX386859B (es) * | 2014-02-05 | 2025-03-19 | Lek Pharmaceuticals | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. |
| CN104844520B (zh) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| CN104844521B (zh) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | 抗前列腺癌药物恩杂鲁胺的合成方法 |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| LT3226842T (lt) * | 2014-12-05 | 2021-03-25 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| JP6830892B2 (ja) | 2014-12-05 | 2021-02-17 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 抗癌性組成物 |
| DK3372585T3 (da) * | 2014-12-19 | 2022-05-30 | Aragon Pharmaceuticals Inc | Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse |
| MX383748B (es) * | 2014-12-19 | 2025-03-14 | Aragon Pharmaceuticals Inc | Procesos para la preparación de un compuesto de diariltiohidantoína. |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR102564925B1 (ko) * | 2015-01-20 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
| CN105732575A (zh) * | 2015-02-06 | 2016-07-06 | 苏州晶云药物科技有限公司 | 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法 |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| RU2019115778A (ru) * | 2015-04-21 | 2019-06-24 | Джи Ти Икс, ИНК. | Селективные лиганды - разрушители андрогенных рецепторов (sard) и способы их применения |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| AU2016280255A1 (en) | 2015-06-18 | 2018-02-08 | Cephalon, Inc. | 1, 4-substituted piperidine derivatives |
| MX379846B (es) | 2015-06-18 | 2025-03-11 | 89Bio Ltd | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. |
| TWI726969B (zh) * | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| CA3030184A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| WO2018037342A1 (en) | 2016-08-22 | 2018-03-01 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| ES2952770T3 (es) * | 2016-12-13 | 2023-11-06 | Watson Lab Inc | Formas de estado sólido de apalutamida |
| CN113563311A (zh) * | 2017-08-07 | 2021-10-29 | 正大天晴药业集团股份有限公司 | 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 |
| CN109422737B (zh) * | 2017-08-22 | 2021-07-30 | 上海时莱生物技术有限公司 | 咪唑酮类雄激素受体拮抗剂、其制备方法和用途 |
| CN111479805B (zh) | 2017-08-29 | 2024-08-13 | 罗格斯新泽西州立大学 | 治疗性吲唑 |
| CN109422725A (zh) * | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| MX2020003845A (es) | 2017-10-16 | 2020-11-06 | Aragon Pharmaceuticals Inc | Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| US12202815B2 (en) | 2018-09-05 | 2025-01-21 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| SG11202108300VA (en) | 2019-02-01 | 2021-08-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Crystal of diarylthiohydantoin compound |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| WO2021043245A1 (en) * | 2019-09-06 | 2021-03-11 | Ono Pharmaceutical Co., Ltd. | Hydantoin derivative |
| CN110452166A (zh) * | 2019-09-06 | 2019-11-15 | 浙江朗华制药有限公司 | 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法 |
| US20210323931A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
| CN113698317B (zh) * | 2020-05-20 | 2025-09-30 | 苏州科伦药物研究有限公司 | 阿帕他胺的合成方法、其中间体及合成方法 |
| CN114315805A (zh) * | 2020-10-09 | 2022-04-12 | 中国科学院上海药物研究所 | 芳环并环状内脂类硫代乙内酰脲化合物及制备方法和用途 |
| WO2022226349A1 (en) * | 2021-04-22 | 2022-10-27 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| CN115650954A (zh) * | 2022-10-24 | 2023-01-31 | 江苏海悦康医药科技有限公司 | 阿帕他胺有关物质的制备方法 |
| CN120112517A (zh) * | 2022-10-28 | 2025-06-06 | 南京明德新药研发有限公司 | 桥环类化合物及其在药学上的应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3823240A (en) | 1970-10-06 | 1974-07-09 | Rhone Poulenc Sa | Fungicidal hydantoin derivatives |
| GB1472467A (en) | 1974-04-19 | 1977-05-04 | Wyeth John & Brother Ltd | Thiohydantoins |
| FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
| DE2614831A1 (de) | 1976-04-06 | 1977-10-20 | Bayer Ag | 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| MC1220A1 (fr) | 1977-10-28 | 1979-07-20 | Hoffmann La Roche | Nouveaux derives d'imidazolidine |
| CA1138334A (en) | 1977-10-28 | 1982-12-28 | Karl Bernauer | Pharmaceutical preparations containing certain urea derivatives |
| AU531493B2 (en) | 1977-12-01 | 1983-08-25 | The Wellcome Foundation Limited | Thiohydantion derivatives |
| EP0004723A1 (en) | 1978-03-30 | 1979-10-17 | Beecham Group Plc | Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them |
| FR2449448B1 (fr) | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation |
| FI801184A7 (fi) | 1979-04-24 | 1981-01-01 | F Hoffmann La Roche & Co | Menetelmä imidatsolidiini-johdannaisten valmistamiseksi. |
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| JPS57197268A (en) | 1981-05-29 | 1982-12-03 | Sumitomo Chem Co Ltd | Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient |
| EP0091596B1 (de) | 1982-04-08 | 1991-09-11 | Shell Internationale Researchmaatschappij B.V. | Neue Hydantoine, ihre Herstellung und Verwendung |
| US4473393A (en) | 1982-08-06 | 1984-09-25 | Buffalo Color Corporation | Pesticidal thiohydantoin compositions |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| JPS59210083A (ja) | 1983-05-13 | 1984-11-28 | Otsuka Chem Co Ltd | １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤 |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS6092285A (ja) | 1983-10-26 | 1985-05-23 | Shionogi & Co Ltd | イソオキサゾ−ル系環状尿素類 |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| DE3604042A1 (de) | 1986-02-08 | 1987-08-13 | Hoechst Ag | Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| JPS649978A (en) | 1987-07-02 | 1989-01-13 | Shionogi & Co | Perfluoroalkylisoxazole derivative |
| US4859228A (en) | 1987-07-16 | 1989-08-22 | Ici Americas Inc | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| FR2619381B1 (fr) | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| US5614620A (en) | 1988-03-30 | 1997-03-25 | Arch Development Corporation | DNA binding proteins including androgen receptor |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
| JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE3835168A1 (de) | 1988-10-15 | 1990-04-19 | Bayer Ag | N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| FR2656302B1 (fr) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveau procede de preparation de l'anandron et derives de l'anandron. |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2715402B1 (fr) | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| WO1996004248A1 (en) | 1994-07-29 | 1996-02-15 | Suntory Limited | Imidazolidine derivative and use thereof |
| FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| DE19540027A1 (de) | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
| FR2741346B1 (fr) | 1995-11-16 | 1997-12-19 | Roussel Uclaf | Nouveau procede de preparation de derives phenylimidazolidine |
| FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| EP0876354A1 (en) | 1995-11-28 | 1998-11-11 | American Home Products Corporation | 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives |
| TW418195B (en) | 1995-11-28 | 2001-01-11 | American Home Prod | 2-thioxo-imidazolidin-4-one derivatives |
| US5554607A (en) | 1995-11-28 | 1996-09-10 | American Home Products Corporation | Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| FR2742749B1 (fr) | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
| US6489163B1 (en) | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
| US5726061A (en) | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
| US7053263B2 (en) | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
| JP2001511146A (ja) | 1997-02-03 | 2001-08-07 | ダウ・アグロサイエンス・エル・エル・シー | 殺菌・殺カビ剤としてのピリジン環上にカルボン酸誘導基を有する２−メトキシイミノ−２−（ピリジニルオキシメチル）フェニルアセトアミド |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6506607B1 (en) | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
| WO1999065494A1 (en) | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| BR9914018A (pt) | 1998-09-22 | 2001-07-03 | Yamanouchi Pharmaceuticals Co | Derivado de cianofenila |
| ATE240944T1 (de) | 1998-09-22 | 2003-06-15 | Degussa | Verfahren zur herstellung von imidazolidin-2,4- dionen |
| WO2000026195A1 (en) | 1998-10-30 | 2000-05-11 | G.D. Searle & Co. | Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| WO2000044731A1 (en) | 1999-01-27 | 2000-08-03 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| WO2001007048A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6479063B2 (en) | 1999-12-27 | 2002-11-12 | Kenneth Weisman | Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis |
| ES2284641T3 (es) | 2000-05-31 | 2007-11-16 | Tanabe Seiyaku Co., Ltd. | Inhibidores de la adhesion celular mediada por alfa-l-beta-2. |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| WO2002053155A1 (en) | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
| FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
| US6710037B2 (en) | 2001-05-01 | 2004-03-23 | Schering Corporation | Method of treating androgen-dependent disorders |
| CN1596253A (zh) | 2001-10-01 | 2005-03-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用作抗炎药的螺－乙内酰脲化合物 |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| DE10218963A1 (de) | 2002-04-27 | 2003-11-20 | Aventis Pharma Gmbh | Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| WO2004016758A2 (en) | 2002-08-15 | 2004-02-26 | Genzyme Corporation | Brain endothelial cell expression patterns |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| FR2845384B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| CA2500977A1 (en) | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof in therapeutics |
| FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| JP2004252175A (ja) | 2003-02-20 | 2004-09-09 | Kyocera Mita Corp | 現像装置、画像形成装置および現像剤の回収方法 |
| BRPI0411083A (pt) | 2003-06-12 | 2006-07-25 | Astellas Pharma Inc | derivado de benzamida ou sais do mesmo |
| EP1634874A4 (en) | 2003-06-12 | 2008-04-02 | Chugai Pharmaceutical Co Ltd | imidazolidine |
| EP1636205A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| TW200523252A (en) | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| EP1709152A4 (en) | 2003-12-15 | 2007-11-07 | Univ California | MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR |
| DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
| WO2005099693A2 (en) | 2004-02-24 | 2005-10-27 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
| WO2005089752A2 (en) | 2004-03-15 | 2005-09-29 | Ptc Therapeutics, Inc. | Tetra-cyclic carboline derivatives for inhibiting angiogenesis |
| EP1621539A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| JP4912148B2 (ja) | 2004-08-03 | 2012-04-11 | 中外製薬株式会社 | 新規イミダゾリジン誘導体 |
| EP1790640A4 (en) | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF |
| KR101782236B1 (ko) | 2005-05-13 | 2017-09-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| FR2889189A1 (fr) | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CN101032486B (zh) | 2006-03-08 | 2011-05-11 | 张宏 | 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂 |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| PT2368550E (pt) | 2006-03-27 | 2013-12-03 | Univ California | Modulador do receptor de androgénios para o tratamento de cancro da próstata e doenças associadas ao receptor de androgénios |
| CN101460467B (zh) | 2006-03-29 | 2012-09-19 | 加利福尼亚大学董事会 | 二芳基硫代乙内酰脲化合物 |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| UY31432A1 (es) * | 2007-10-26 | 2009-05-29 | Compuestos de diarilhidantoina | |
| CA2753425A1 (en) * | 2009-02-24 | 2010-09-02 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
| EA028869B1 (ru) * | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Модуляторы рецептора андрогенов и их применение |
| SI2538785T1 (en) | 2010-02-24 | 2018-05-31 | Medivation Prostate Therapeutics Llc | Methods for the synthesis of diarylthiohidantoin and diarylhydantoin compounds |
| US20130253035A1 (en) | 2010-08-16 | 2013-09-26 | Duke University | Camkk-beta as a target for treating cancer |
| EP2709614A4 (en) | 2011-05-17 | 2015-04-15 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER |
| US20130045204A1 (en) | 2011-08-19 | 2013-02-21 | The University Of British Columbia | Fluorinated bisphenol ether compounds and methods for their use |
| US20130079241A1 (en) | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| PL2785349T5 (pl) | 2011-11-30 | 2023-01-30 | Astrazeneca Ab | Kombinacja do leczenia nowotworu |
| MY180834A (en) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
-
2011
- 2011-02-16 EA EA201590590A patent/EA028869B1/ru unknown
- 2011-02-16 HU HUE16184263A patent/HUE037389T2/hu unknown
- 2011-02-16 PL PL16184263T patent/PL3124481T3/pl unknown
- 2011-02-16 DK DK16184263.8T patent/DK3124481T3/en active
- 2011-02-16 AU AU2011218173A patent/AU2011218173C1/en not_active Ceased
- 2011-02-16 EP EP11745183.1A patent/EP2536708A4/en not_active Withdrawn
- 2011-02-16 SM SM20180277T patent/SMT201800277T1/it unknown
- 2011-02-16 KR KR1020127023906A patent/KR101819199B1/ko not_active Expired - Fee Related
- 2011-02-16 KR KR1020187000615A patent/KR101972719B1/ko not_active Expired - Fee Related
- 2011-02-16 EA EA201792046A patent/EA201792046A1/ru unknown
- 2011-02-16 SG SG10201907588XA patent/SG10201907588XA/en unknown
- 2011-02-16 ES ES16184263T patent/ES2668380T3/es active Active
- 2011-02-16 PT PT161842638T patent/PT3124481T/pt unknown
- 2011-02-16 EP EP14188300.9A patent/EP2824102B1/en active Active
- 2011-02-16 PH PH1/2012/501652A patent/PH12012501652A1/en unknown
- 2011-02-16 BR BR112012020558-7A patent/BR112012020558B1/pt not_active IP Right Cessation
- 2011-02-16 EA EA201270720A patent/EA023981B1/ru unknown
- 2011-02-16 MX MX2015009660A patent/MX355915B/es unknown
- 2011-02-16 CA CA2787083A patent/CA2787083C/en active Active
- 2011-02-16 CN CN201410012317.7A patent/CN103724322B/zh not_active Expired - Fee Related
- 2011-02-16 JP JP2012554001A patent/JP5918147B2/ja not_active Expired - Fee Related
- 2011-02-16 SG SG2012059945A patent/SG183302A1/en unknown
- 2011-02-16 CN CN201710229373.XA patent/CN106983749A/zh active Pending
- 2011-02-16 WO PCT/US2011/025106 patent/WO2011103202A2/en not_active Ceased
- 2011-02-16 MX MX2012009453A patent/MX2012009453A/es active IP Right Grant
- 2011-02-16 RS RS20180649A patent/RS57309B1/sr unknown
- 2011-02-16 SI SI201131455T patent/SI3124481T1/en unknown
- 2011-02-16 CN CN201180009819.9A patent/CN102884057B/zh not_active Expired - Fee Related
- 2011-02-16 EP EP16184263.8A patent/EP3124481B1/en active Active
- 2011-02-16 EP EP18161153.4A patent/EP3357917A1/en not_active Withdrawn
- 2011-02-16 SG SG10201501202TA patent/SG10201501202TA/en unknown
- 2011-02-16 LT LTEP16184263.8T patent/LT3124481T/lt unknown
- 2011-02-16 US US13/579,009 patent/US9108944B2/en not_active Expired - Fee Related
-
2012
- 2012-07-01 IL IL220703A patent/IL220703A/en active IP Right Grant
-
2015
- 2015-02-17 IL IL23727315A patent/IL237273B/en active IP Right Grant
- 2015-02-17 IL IL237272A patent/IL237272A/en active IP Right Grant
- 2015-03-12 US US14/656,031 patent/US9481664B2/en not_active Expired - Fee Related
- 2015-08-07 PH PH12015501738A patent/PH12015501738B1/en unknown
- 2015-08-07 PH PH12015501737A patent/PH12015501737B1/en unknown
- 2015-10-22 ZA ZA2015/07863A patent/ZA201507863B/en unknown
- 2015-10-22 ZA ZA2015/07865A patent/ZA201507865B/en unknown
-
2016
- 2016-03-31 JP JP2016073172A patent/JP6141484B2/ja not_active Expired - Fee Related
- 2016-09-09 US US15/261,041 patent/US10023556B2/en active Active
-
2017
- 2017-05-01 JP JP2017091441A patent/JP6391076B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-28 HR HRP20180848TT patent/HRP20180848T1/hr unknown
- 2018-06-06 CY CY20181100592T patent/CY1120297T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519733A5 (OSRAM) | ||
| JP5210867B2 (ja) | 置換ベンゾイミダゾールおよびその製造方法 | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| WO2005082865A1 (ja) | 縮合二環性ピリミジン誘導体 | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| JP2013502429A5 (OSRAM) | ||
| KR20010083055A (ko) | 글리코겐 신타제 키나제 3의 억제제 | |
| JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
| US20100324009A1 (en) | Substituted Sulfonamide Compounds | |
| JP2015503529A5 (OSRAM) | ||
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| WO2003037877A1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | |
| WO2012008563A1 (ja) | 含窒素芳香族複素環誘導体 | |
| CA2351725A1 (en) | Substituted pyrazoles as p38 kinase inhibitors | |
| JP2013503846A (ja) | ベンズイミダゾール誘導体 | |
| JP6969800B2 (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| CN109071523A (zh) | 一种脲类化合物、其制备方法及其医药用途 | |
| AU2017289021A1 (en) | Novel pyrazole derivative as ALK5 inhibitor and uses thereof | |
| EP1625119B1 (en) | Substituted-1-phthalazinamines as vr-1 antagonists | |
| US20250179013A1 (en) | Inhibitors of rna helicase dhx9 and uses thereof | |
| JP2020516672A5 (OSRAM) | ||
| JPWO2020165834A5 (OSRAM) | ||
| CN104470918A (zh) | 芳香族杂环衍生物及医药 | |
| WO2005085212A1 (ja) | 置換ピリミジン誘導体 | |
| US20060160861A1 (en) | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |